European Meeting on Complement in Human Disease (EMCHD), Lübeck, Germany

Sessions

Satellite symposium - oral session: Inhibition of the C5a/C5aR1 axis in inflammation
Speaker: Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx
Day/time: Monday, September 2, 3:00 – 3:30p CET

Satellite symposium - panel discussion: Targeting C3 and/or C5 Pathways
InflaRx participant: Prof. Niels C. Riedemann
Day/time: Monday, September 2, 4:00 – 5:00p CET

Lunch seminar: Complement C5a/C5aR inhibition in human disease with best-in-class inhibitors
InflaRx speakers: Niels Riedemann, Chief Executive Officer and Founder, Renfeng Guo, Chief Scientific Officer and Founder, Camilla Chong, Chief Medical Officer
Day/time: Tuesday, September 3, 12:45 – 1:30p CET

Poster Presentations

Poster title: INF904, a novel oral C5a receptor 1 (C5aR1) antagonist, shows promising therapeutic effects in inflammatory disease models
Poster number: P19
Authors: Zhongli Xu, Rui Liu, Ophelia Chen, Bruce P. Burnett, Maria Habel, Renfeng Guo

Poster title: Preclinical pharmacological characterization of INF904, an oral small molecule antagonist to complement 5a receptor1 (C5aR1)
Poster number: P20
Authors: Rui Liu, Zhongli Xu, Ophelia Chen, Bruce P. Burnett, Maria Habel, Renfeng Guo

preliminary conference program